Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
394
mi
from 43215
St Louis, MO
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
394
mi
from 43215
St Louis, MO
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
450
mi
from 43215
Somers Point, NJ
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
450
mi
from 43215
Somers Point, NJ
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
425
mi
from 43215
Voorhees, NJ
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
425
mi
from 43215
Voorhees, NJ
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
481
mi
from 43215
New York, NY
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
481
mi
from 43215
New York, NY
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
355
mi
from 43215
Rochester, NY
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
355
mi
from 43215
Rochester, NY
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
306
mi
from 43215
Winston-Salem, NC
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
2026
mi
from 43215
Portland, OR
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
2026
mi
from 43215
Portland, OR
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
937
mi
from 43215
Fort Worth, TX
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
994
mi
from 43215
Galveston, TX
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
994
mi
from 43215
Galveston, TX
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
413
mi
from 43215
Hampton, VA
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
413
mi
from 43215
Hampton, VA
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
Clinical Research Facility
1778
mi
from 43215
Spokane, WA
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
Clinical Research Facility
1778
mi
from 43215
Spokane, WA
Click here to add this to my saved trials
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated:  11/2/2015
1805
mi
from 43215
Ponce,
BOSS Study: A Study of Fuzeon Using the Needle-Free Biojector 2000 in Patients With HIV-1 Infection
Biojector 2000 Open-Label Safety Study (BOSS) to Evaluate Signs and Symptoms Associated With a Needle-free Injection Device for Administration of Fuzeon to Patients With HIV-1 Infection
Status: Enrolling
Updated: 11/2/2015
1805
mi
from 43215
Ponce,
Click here to add this to my saved trials
Human Immune Responses Toward HIV-1 Envelope Antigens
Human Immune Responses Toward HIV-1 Envelope Antigens
Status: Enrolling
Updated:  11/4/2015
St. Jude Children's Research Hospital
507
mi
from 43215
Memphis, TN
Human Immune Responses Toward HIV-1 Envelope Antigens
Human Immune Responses Toward HIV-1 Envelope Antigens
Status: Enrolling
Updated: 11/4/2015
St. Jude Children's Research Hospital
507
mi
from 43215
Memphis, TN
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
1660
mi
from 43215
Phoenix, AZ
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
1660
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
1976
mi
from 43215
Long Beach, CA
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
1976
mi
from 43215
Long Beach, CA
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
2108
mi
from 43215
San Francisco, CA
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
1160
mi
from 43215
Denver, CO
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
1160
mi
from 43215
Denver, CO
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
328
mi
from 43215
Washington,
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
328
mi
from 43215
Washington,
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
966
mi
from 43215
Fort Lauderdale, FL
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
966
mi
from 43215
Fort Lauderdale, FL
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
797
mi
from 43215
Orlando, FL
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
797
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
1281
mi
from 43215
Santa Fe, NM
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
1281
mi
from 43215
Santa Fe, NM
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
353
mi
from 43215
Chapel Hill, NC
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
348
mi
from 43215
Charlotte, NC
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
348
mi
from 43215
Charlotte, NC
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
905
mi
from 43215
Dallas, TX
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated:  11/5/2015
GSK Investigational Site
316
mi
from 43215
Toronto,
A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir
A Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-infected Adult Subjects With Raltegravir Resistance
Status: Enrolling
Updated: 11/5/2015
GSK Investigational Site
316
mi
from 43215
Toronto,
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
UCLA CARE Center CRS (601)
1972
mi
from 43215
Los Angeles, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
UCLA CARE Center CRS (601)
1972
mi
from 43215
Los Angeles, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Ucsd, Avrc Crs (701)
1951
mi
from 43215
San Diego, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Ucsd, Avrc Crs (701)
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Harbor-UCLA Med. Ctr. CRS (603)
1983
mi
from 43215
Torrance, CA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Harbor-UCLA Med. Ctr. CRS (603)
1983
mi
from 43215
Torrance, CA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
University of Colorado Hospital CRS (6101)
1153
mi
from 43215
Aurora, CO
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
University of Colorado Hospital CRS (6101)
1153
mi
from 43215
Aurora, CO
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Georgetown University CRS (GU CRS) (1008)
328
mi
from 43215
Washington,
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Georgetown University CRS (GU CRS) (1008)
328
mi
from 43215
Washington,
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Northwestern University CRS (2701)
274
mi
from 43215
Chicago, IL
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Northwestern University CRS (2701)
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
643
mi
from 43215
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Beth Israel Deaconess Med. Ctr., ACTG CRS (103)
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Brigham and Women's Hosp. ACTG CRS (107)
643
mi
from 43215
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Brigham and Women's Hosp. ACTG CRS (107)
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Massachusetts General Hospital ACTG CRS (101)
643
mi
from 43215
Boston, MA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Massachusetts General Hospital ACTG CRS (101)
643
mi
from 43215
Boston, MA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Henry Ford Hosp. CRS (31472)
163
mi
from 43215
Detroit, MI
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Henry Ford Hosp. CRS (31472)
163
mi
from 43215
Detroit, MI
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Washington U CRS (2101)
394
mi
from 43215
St. Louis, MO
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Washington U CRS (2101)
394
mi
from 43215
St. Louis, MO
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Cooper Univ. Hosp. CRS (31476)
418
mi
from 43215
Camden, NJ
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Cooper Univ. Hosp. CRS (31476)
418
mi
from 43215
Camden, NJ
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Cornell CRS (7804)
477
mi
from 43215
New York, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Cornell CRS (7804)
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
NY Univ. HIV/AIDS CRS (401)
477
mi
from 43215
New York, NY
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
NY Univ. HIV/AIDS CRS (401)
477
mi
from 43215
New York, NY
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Unc Aids Crs
353
mi
from 43215
Chapel Hill, NC
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Unc Aids Crs
353
mi
from 43215
Chapel Hill, NC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Duke Univ. Med. Ctr. Adult CRS (1601)
354
mi
from 43215
Durham, NC
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Duke Univ. Med. Ctr. Adult CRS (1601)
354
mi
from 43215
Durham, NC
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Univ. of Cincinnati CRS (2401)
98
mi
from 43215
Cincinnati, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Univ. of Cincinnati CRS (2401)
98
mi
from 43215
Cincinnati, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Metro Health CRS (2503)
127
mi
from 43215
Cleveland, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Metro Health CRS (2503)
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Case CRS (2501)
127
mi
from 43215
Cleveland, OH
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Case CRS (2501)
127
mi
from 43215
Cleveland, OH
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Hosp. of the Univ. of Pennsylvania CRS (6201)
416
mi
from 43215
Philadelphia, PA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Hosp. of the Univ. of Pennsylvania CRS (6201)
416
mi
from 43215
Philadelphia, PA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Pitt CRS (1001)
162
mi
from 43215
Pittsburgh, PA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Pitt CRS (1001)
162
mi
from 43215
Pittsburgh, PA
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Houston AIDS Research Team CRS (31473)
991
mi
from 43215
Houston, TX
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Houston AIDS Research Team CRS (31473)
991
mi
from 43215
Houston, TX
Click here to add this to my saved trials
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated:  11/10/2015
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
344
mi
from 43215
Richmond, VA
Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Status: Enrolling
Updated: 11/10/2015
Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
344
mi
from 43215
Richmond, VA
Click here to add this to my saved trials